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1. PUBLIC HEALTH STATEMENT
 
This Statement was prepared to give you information about
 
chlorobenzene and to emphasize the human health effects that may result
 
from exposure to it. The Environmental Protection Agency (EPA) has
 
identified 1,177 sites on its National Priorities List (NPL).
 
Chlorobenzene has been found at 97 of these sites. However, we do not
 
know how many of the 1,177 NPL sites have been evaluated for
 
chlorobenzene. As EPA evaluates more sites, the number of sites at
 
which chlorobenzene is found may change. The information is important
 
for you because chlorobenzene may cause harmful health effects and
 
because these sites are potential or actual sources of human exposure to
 
chlorobenzene.
 
When a chemical is released from a large area, such as an
 
industrial plant, or from a container, such as a drum or bottle, it
 
enters the environment as a chemical emission. This emission, which is
 
also called a release, does not always lead to exposure. You can be
 
exposed to a chemical only when you come into contact with the chemical.
 
You may be exposed to it in the environment by breathing, eating, or
 
drinking substances containing the chemical or from skin contact with
 
it.
 
If you are exposed to a hazardous substance such as chlorobenzene,
 
several factors will determine whether harmful health effects will occur
 
and what the type and severity of those health effects will be. These
 
factors include the dose (how much), the duration (how long), the route
 
or pathway by which you are exposed (breathing, eating, drinking, or
 
skin contact), the other chemicals to which you are exposed, and your
 
individual characteristics such as age, sex, nutritional status, family
 
traits, life style, and state of health.
 
1.1WHAT IS CHLOROBENZENE?
 
Chlorobenzene is a colorless liquid with an almond-like odor. The
 
compound does not occur widely in nature, but is manufactured for use as
 
a solvent (a substance used to dissolve other substances) and is used in
 
the production of other chemicals. Chlorobenzene persists in soil
 
(several months), in air (3.5 days), and water (less than 1 day).
 
Additional information can be found in Chapters 3, 4, and 5.
 
1.2 HOW MIGHT I BE EXPOSED TO CHLOROBENZENE?
 
There is potential for humans to be exposed to chlorobenzene by
 
breathing contaminated air, by drinking water or eating food
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contaminated with chlorobenzene, or by getting chlorobenzene­
contaminated soil on the skin. These exposures are most likely to occur
 
in the workplace or in the vicinity of chemical waste sites.
 
Occupational exposure occurs primarily through breathing the
 
chemical. Personnel engaged in the production and handling of
 
chlorobenzene would be at greatest risk. Levels of chlorobenzene in the
 
air at several industrial sites during normal operations were found to
 
be below allowable federal standards.
 
Exposure in humans could occur in persons living or working in the
 
vicinity of hazardous waste sites if emissions to water, air, and soil
 
are not adequately controlled. Chlorobenzene has been found at 97 out
 
of 1,177 NPL hazardous waste sites in the United States. Thus, federal
 
and state surveys suggest that chlorobenzene is not a widespread
 
environmental contaminant. The chemical has not been detected in
 
surface water, although a few ground water systems have been found with
 
chlorobenzene levels in the parts per billion (ppb) range. Background
 
levels of less than 1 ppb were detected in air samples from urban and
 
suburban areas. No information of the occurrence of chlorobenzene in
 
food has been found. Additional information on the potential for human
 
exposure is presented in Chapter 5.
 
1.3 HOW CAN CHLOROBENZENE ENTER AND LEAVE MY BODY?
 
Chlorobenzene enters your body when you breathe in air containing
 
it, when you drink water or eat food containing it, or when it comes in
 
contact with your skin. Human exposure to contaminated water could
 
occur near hazardous waste sites where chlorobenzene is present.
 
Significant exposure to chlorobenzene is not expected to occur by
 
getting chlorobenzene contaminated soil on your skin. When
 
chlorobenzene enters your body, most of it is expelled from your lungs
 
in the air we breathe out and in urine. Additional information is
 
presented in Chapter 2.
 
1.4 HOW CAN CHLOROBENZENE AFFECT MY HEALTH?
 
Workers exposed to high levels of chlorobenzene complained of
 
headaches, numbness, sleepiness, nausea, and vomiting. However, it is
 
not known if chlorobenzene alone was responsible for these health
 
effects since the workers may have also been exposed to other chemicals
 
at the same time. Mild to severe depression of functions of parts of
 
the nervous system is a common response to exposure to a wide variety of
 
industrial solvents (a substance that dissolves other substances).
 
In animals, exposure to high concentrations of chlorobenzene
 
affects the brain, liver, and kidneys. Unconsciousness, tremors and
 
restlessness have been observed. The chemical can cause severe injury
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to the liver and kidneys. Data indicate that chlorobenzene does not
 
affect reproduction or cause birth defects. Studies in animals have
 
shown that chlorobenzene can produce liver nodules, providing some but
 
not clear evidence of cancer risk. Additional information on health
 
effects is presented in Chapter 2.
 
1.5 WHAT LEVELS OF EXPOSURE HAVE RESULTED IN HARMFUL HEALTH EFFECTS?
 
Harm to human health from breathing, eating or drinking
 
chlorobenzene is not established (Tables l-l and l-3). Tables l-2 and
 
l-4 show the relationship between exposure to chlorobenzene and known
 
health effects in animals. A Minimal Risk Level (MRL) is included in
 
Table l-3. The MRL was derived from animal data for long-term exposure,
 
as described in Chapter 2 and in Table 2-2. The MRL provides a basis
 
for comparison with levels that people might encounter either in the air
 
or in food or drinking water. If a person is exposed to chlorobenzene
 
at an amount below the MRL, it is not expected that harmful (noncancer)
 
health effects will occur. Because this level is based only on
 
information currently available, some uncertainty is always associated
 
with it. Also, because the method for deriving MRLs does not use any
 
information about cancer, a MRL does not imply anything about the
 
presence, absence, or level of risk for cancer. Further information on
 
the levels of chlorobenzene that have been observed to cause health
 
effects in animals is presented in Chapter 2.
 
1.6 	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
 
CHLOROBENZENE?
 
Exposure to chlorobenzene can be determined by measuring the
 
chemical or its metabolite in urine, exhaled air, blood, and body fat.
 
Tests are not routinely available at the doctor's office. Specific
 
tests are available that can determine if exposure is currently
 
occurring or has occurred very recently, but not whether exposure
 
occurred in the past. Further, levels in the various media stated above
 
do not predict adverse health effects. Additional information on how
 
chlorobenzene can be measured in exposed humans is given in Chapters 2
 
and 6.
 




  
 
8
 
1. PUBLIC HEALTH STATEMENT
 
1.7	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN
 
HEALTH?
 
The Federal Government has developed regulatory standards and
 
advisories to protect individuals from potential health effects of
 
cholorobenzene in the environment. The Environmental Protection Agency
 
has proposed that the maximum level of chlorobenzene in drinking water
 
be 0.1 parts per million (ppm). For short-term exposures to drinking
 
water, EPA has recommended that drinking water levels not exceed 2 ppm
 
for up to ten days. The Occupational Safety and Health Administration
 
(OSHA) has established a legally enforceable minimum limit of 75 ppm of
 
chlorobenzene in workplace air for an 8 hour/day, 40-hour work week.
 
Additional information regarding federal and state regulations is
 
presented in Chapter 7.
 
1.8	 WHERE CAN I GET MORE INFORMATION?
 
If you have any more questions or concerns not covered here, please
 
contact your State Health or Environmental Department or:
 
Agency for Toxic Substance and Disease Registry
 
Division of Toxicology
 
1600 Clifton Road, E-29
 
Atlanta, Georgia 30333
 
This agency can also give you information on the location of the
 
nearest occupational and environmental health clinics. Such clinics
 
specialize in recognizing, evaluating, and treating illnesses that
 
result from exposure to hazardous substances.
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2. HEALTH EFFECTS
 
2.1 INTRODUCTION
 
This chapter contains descriptions and evaluations of studies and
 
interpretation of data on the health effects associated with exposure to
 
chlorobenzene. Its purpose is to present levels of significant exposure
 
for chlorobenzene based on toxicological studies, epidemiological
 
investigations, and environmental exposure data. This information is
 
presented to provide public health officials, physicians, toxicologists,
 
and other interested individuals and groups with (1) an overall
 
perspective of the toxicology of chlorobenzene and (2) a depiction of
 
significant exposure levels associated with various adverse health
 
effects.
 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
 
To help public health professionals address the needs of persons
 
living or working near hazardous waste sites, the data in this section
 
are organized first by route of exposure -- inhalation, oral, and
 
dermal -- and then by health effect -- death, systemic, immunological,
 
neurological, developmental, reproductive, genotoxic, and carcinogenic
 
effects. These data are discussed in terms of three exposure periods -­
acute, intermediate, and chronic.
 
Levels of significant exposure for each exposure route and duration
 
(for which data exist) are presented in tables and illustrated in
 
figures. The points in the figures showing no-observed-adverse-effect
 
levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs)
 
reflect the actual doses (levels of exposure) used in the studies.
 
LOAELS have been classified into "less serious" or "serious" effects.
 
These distinctions are intended to help the users of the document
 
identify the levels of exposure at which adverse health effects start to
 
appear, determine whether or not the intensity of the effects varies
 
with dose and/or duration, and place into perspective the possible
 
significance of these effects to human health.
 
The significance of the exposure levels shown on the tables and
 
graphs may differ depending on the user's perspective. For example,
 
physicians concerned with the interpretation of clinical findings in
 
exposed persons or with the identification of persons with the potential
 
to develop such disease may be interested in levels of exposure
 
associated with "serious effects". Public health officials and project
 
managers concerned with response actions at Superfund sites may want
 
information on levels of exposure associated with more subtle effects in
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humans or animals (LOAELs) or exposure levels below which no adverse
 
effects (NOAELs) have been observed. Estimates of levels posing minimal
 
risk to humans (minimal risk levels, MRLs) are of interest to health
 
professionals and citizens alike.
 
Estimates of exposure levels posing minimal risk to humans (MRLs)
 
have been made, where data were believed reliable, for the most
 
sensitive noncancer end point for each exposure duration. MRLs include
 
adjustments to reflect human variability and, where appropriate, the
 
uncertainty of extrapolating from laboratory animal data to humans.
 
Although methods have been established to derive these levels (Barnes
 
et al. 1987; EPA 1989a), uncertainties are associated with the
 
techniques.
 
2.2.1 Inhalation Exposure
 
2.2.1.1 Death
 
No studies were located regarding lethality in humans following
 
inhalation exposure to chlorobenzene.
 
The acute lethality of chlorobenzene is relatively low in animals.
 
Exposure to concentrations of 20 mg/L (4,300 ppm) for 2 hours resulted
 
in 100% mortality in mice (Rozenbaum et al. 1947). Rabbits died 2 weeks
 
after chlorobenzene exposure to concentrations of about 537 ppm
 
(Rozenbaum et al. 1947).
 
The highest NOAEL values and all reliable LOAEL values for death in
 
each species and duration category are recorded in Table 2-1 and plotted
 
in Figure 2-1.
 
2.2.1.2 Systemic Effects
 
No studies were located regarding effects on the respiratory,
 
cardiovascular, gastrointestinal, hematological, musculoskeletal,
 
hepatic, renal, and dermal/ocular systems in humans following inhalation
 
exposure to chlorobenzene.
 
As shown in Table 2-1 and Figure 2-1, animal studies indicate that
 
chlorobenzene induces injury to the liver and kidneys following
 
intermediate and chronic inhalation exposures.
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Hematological. Based on a small number of studies, chlorobenzene
 
may cause hematological changes. There were dose and time-related
 
effects on red blood cell parameters, primarily an increase in
 
reticulocyte count which increased in rats but not in rabbits exposed to
 
vapors of chlorobenzene at concentrations > 75 ppm for 24 weeks (Dilley
 
1977). Other hematological parameters (red blood cell count,
 
hemoglobins, hematocrit, and white blood cell count) were variable and
 
were comparable to controls at the end of the test. Slight leukopenia
 
and lymphocytosis occurred in mice exposed to chlorobenzene (0.1 mg/L)
 
for 3 months (Zub 1978). In the absence of more detailed experimental
 
data and information on compound purity, it is not certain if the
 
effects in mice were compound-related. Further, these effects have not
 
been confirmed at comparable doses in other species. Thus, it appears
 
that hematological effects may not be sensitive indicators of
 
chlorobenzene toxicity.
 
Hepatic Effects. No data were found that severe liver damage
 
results from acute exposure to chlorobenzene vapor. Treatment-related
 
congestion of the liver was observed in male rats and to a lesser degree
 
in male rabbits exposed for 24 weeks to > 75 ppm (Dilley 1977). Focal
 
hemorrhages and foci of perivascular lymphocytes were observed.
 
Decreased levels of serum enzymes (lactate dehydrogenase [LDH] and serum
 
glutamic-oxaloacetic transaminase [SGOT]) were observed at the end of
 
the treatment period; the significance of this response is not clear.
 
Nair et al. (1987) reported liver hypertrophy and increased liver
 
weights in male rats exposed to chlorobenzene vapors daily at 150 and
 
450 ppm for two generations. Overall, data suggest liver toxicity may
 
be an area of concern for chlorobenzene exposure in humans.
 
The highest NOAEL values and all reliable LOAEL values for liver
 
toxicity in each species and duration category are recorded in Table 2-l
 
and plotted in Figure 2-l.
 
Renal Effects. A small number of studies demonstrates that the
 
kidney is also a target organ following chlorobenzene exposure and that
 
the effects occur at levels comparable to those causing liver effects.
 
Nair et al. (1987) reported tubular dilatation with eosinophilic
 
material, interstitial nephritis and foci of regenerative epithelium in
 
male rats exposed to vapors of chlorobenzene at 150 and 450 ppm for two
 
generations. There was also treatment-related congestion of the kidneys
 
in rabbits exposed to chlorobenzene at concentrations 275 ppm in
 
animals sacrificed at 5 weeks of a 24 week treatment period (Dilley
 
1977). Interstitial foci of lymphocytes were evident. Overall, data
 
suggest that this effect may also be an area of concern for
 
chlorobenzene exposure in humans.
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The highest NOAEL values and all reliable LOAEL values for renal
 
toxicity in each species and duration category are recorded in Table 2-l
 
and plotted in Figure 2-l.
 
2.2.1.3 Immunological Effects
 
No studies were located regarding the immunological effects in
 
humans or animals following inhalation exposure to chlorobenzene.
 
2.2.1.4  Neurological Effects
 
Chlorobenzene affects the central nervous system. Humans
 
occupationally exposed to chlorobenzene intermittently for up to 2 years at
 
levels above current federal limits displayed signs of neurotoxicity
 
including numbness, cyanosis (from depression of respiratory center),
 
hyperesthesia, and muscle spasms (Rozenbaum et al. 1947). Specific
 
exposure levels and histopathologic data have not been provided.
 
Neurological effects of chlorobenzene have also been reported in
 
animals following inhalation. Acute inhalation exposure produced muscle
 
spasms followed by narcosis in rabbits exposed to 5 mg/L chlorobenzene
 
(1,090 ppm) or greater for 2 hours (Rozenbaum et al. 1947).
 
2.2.1.5 Developmental Effects
 
No studies were located regarding developmental effects in humans
 
following inhalation exposure to chlorobenzene.
 
In rats and rabbits, inhalation of chlorobenzene vapors at
 
concentrations up to 590 ppm during periods of major organogenesis did
 
not produce structural malformations (John et al. 1984). This value has
 
been presented in Table 2-l and plotted in Figure 2-l. The highest dose
 
resulted in maternal toxicity, as indicated by elevation of liver
 
weights (both species) and decreased food consumption and body weight
 
gain (rats only).
 
2.2.1.6 Reproductive Effects
 
No studies were located regarding reproductive effects in humans
 
following inhalation exposure to chlorobenzene.
 
In a two-generation study in rats, chlorobenzene in concentrations
 
up to 450 ppm did not adversely affect reproductive performance or
 
fertility (Nair et al. 1987). This value has been presented in
 
Table 2-l and plotted in Figure 2-1. A slight increase was observed in
 
the incidence of degenerative testicular changes (unilateral and
 
bilateral) in high-dose (450 ppm) males (F0 and F1 generations) and the
 
F1 mid-dose (150 ppm) males. The significance of this finding is
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unclear since the mean mating, pregnancy, and male fertility indices for
 
both F0 and F1 generations were comparable for all groups and the
 
incidences of testicular lesion were identical in F0 and F1 animals.
 
2.2.1.7 Genotoxic Effects
 
No studies were located regarding genotoxic effects in humans or
 
animals following inhalation exposure to chlorobenzene.
 
2.2.1.8 Cancer
 
No studies were located regarding carcinogenic effects in humans or
 
animals following inhalation exposure to chlorobenzene.
 
2.2.2 Oral Exposure
 
2.2.2.1 Death
 
No studies were located regarding lethality in humans following
 
oral exposure to chlorobenzene.
 
Animal studies show that chlorobenzene is lethal following acute,
 
intermediate, and chronic oral exposures. Death occurred within 2 to
 
3 days after a single exposure to 4,000 mg/kg in corn oil by gavage in
 
rats of both sexes, and in mice after a single exposure to 1,000 mg/kg
 
(NTP 1985). Necropsy or histological examination was not performed. In
 
a 14-day repeated-dose gavage study in rats, administration of
 
> 1,000 mg/kg was lethal to all rats by the end of the study (NTP 1985).
 
This dose has been converted to an equivalent concentration of
 
20,000 ppm in food for presentation in Table 1-4. Survival was reduced
 
in rats of both sexes exposed to >500 mg/kg/day and >250 mg/kg/day in
 
mice following intermediate-duration exposure (NTP 1985). The dose of
 
250 mg/kg/day has been converted to an equivalent concentration of
 
1,923 ppm in food for presentation in Table l-4. Clinical signs of
 
toxicity were not observed in mice and rats but histopathologic
 
examination revealed dose-related chemical-induced changes to the liver,
 
kidney, bone marrow, spleen, and thymus. Liver and kidney weights
 
increased in mice and rats, while spleen weights decreased. In chronic
 
oral studies, male rat survival at 120 mg/kg (2,400 ppm) was
 
significantly lower than that of vehicle controls (NTP 1985); however
 
no compound-induced toxic lesions responsible for this reduction in
 
survival were observed.
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The highest NOAEL values and all reliable LOAEL values for death in
 
each species and duration category are recorded in Table 2-2 and plotted
 
in Figure 2-2.
 
2.2.2.2 Systemic Effects
 
No studies in humans were located regarding the effects on the
 
respiratory, cardiovascular, gastrointestinal, hematological,
 
musculoskeletal, hepatic, renal, and dermal/ocular systems following
 
oral exposure to chlorobenzene. The following sections describe effects
 
observed in animals.
 
Hepatic Effects. Animal studies indicate that the liver is 
susceptible to injury by chlorobenzene following oral exposure. Typical 
signs include: increased serum enzymes, altered liver weights, 
degeneration, necrosis, and interference with porphyrin metabolism. In 
acute studies (5 days), effects on porphyrin metabolism occurred at 
1,140 mg/kg/day by gavage (Rimington and Ziegler 1963). Intermediate 
and long-term exposure studies in rats and mice reported organ weight 
increases at 100 (Hazleton 1967) and 125 mg/kg/day (NTP 1985), while 
organ weight increases and microscopic lesions were detected at 
≥ 250 mg/kg/day by the same route (NTP 1985). Focal hepatocytic 
necrosis and degenerative changes in the centrilobular hepatocytes were 
observed in mice. These effects were most apparent in the >500 mg/kg 
dose group in rats. The dose of 250 mg/kg/day has been converted to 
equivalent concentrations of 1,923 ppm (in mice) and 5,000 ppm (in rats) 
in food for presentation in Table l-4. No effects were observed at 
60 mg/kg/day. Based on this value, an intermediate oral MRL of 
0.4 mg/kg/day was calculated as described in the footnote in Table 2-2.
 
This MRL has been converted to an equivalent concentration in food
 
(15 ppm) for presentation in Table 1-3.
 
Renal Effects. Animal studies demonstrate that chlorobenzene can
 
cause injury to the kidney at doses comparable to those which cause
 
liver effects. In a 90-day study, degeneration or focal necrosis of the
 
proximal tubules was observed at >250 mg/kg in mice and >500 mg/kg in
 
rats (NTP 1985). Repeated doses of >100 mg/kg/day for 90 to 99 days
 
(Hazleton 1967) caused an increase in kidney weights.
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The highest NOAEL values and all reliable LOAEL values for renal
 
effects in each species and duration category are recorded in Table 2-2
 
and plotted in Figure 2-2.
 
2.2.2.3 Immunological Effects
 
No studies were located regarding immunological effects in humans
 
following oral exposure to chlorobenzene.
 
Histological studies in mice and rats suggest that chlorobenzene
 
has immunotoxic properties. Mice exposed to chlorobenzene at
 
>250 mg/kg/day by gavage for 13 weeks showed thymic necrosis and
 
lymphoid or myeloid depletion of bone marrow, spleen, or thymus (NTP
 
1985). While histopathologic evidence suggests that chlorobenzene is
 
immunotoxic, a NOAEL cannot be established in this study since immune
 
function tests were not conducted. A LOAEL of 250 mg/kg/day was
 
determined (NTP 1985). This value has been presented in Table 2-2.
 
Since there are no human data on immunotoxic effects and animal data are
 
sparse, firm conclusions can not be made concerning the potential for
 
chlorobenzene to affect the immune system in humans following oral
 
exposure.
 
2.2.2.4 Neurological Effects
 
There is a paucity of data on the effects of chlorobenzene in
 
humans following oral exposure. A two-year-old male swallowed 5 to
 
10 cc of a stain remover which consisted almost entirely of
 
chlorobenzene. He became unconscious, did not respond to skin stimuli,
 
showed muscle spasms, and became cyanotic. The odor of chlorobenzene
 
could be detected in his urine and exhaled air; however, the child
 
recovered uneventfully (Reich 1934).
 
No studies were located regarding neurological effects in animals
 
following oral exposure. In the absence of dose-response data in humans
 
and the lack of animal evidence, the potential for chlorobenzene to
 
produce effects on the nervous system cannot be quantitatively
 
determined.
 
2.2.2.5 Developmental Effects
 
No studies were located regarding the developmental effects in
 
humans following oral exposure to chlorobenzene.
 
Limited data in animals suggest that chlorobenzene is not
 
teratogenic. Rats were administered chlorobenzene (100 or 300 mg/kg) in
 
corn oil by gavage from days 6-15 of gestation (IBT 1977). Fetal
 
weight, external anomalies, and skeletal and soft tissue abnormalities
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did not differ from control animals in any of the measured parameters.
 
Further, data on maternal weight and behavioral effects did not reveal
 
evidence for dose-related effects.
 
2.2.2.6 Reproductive Effects
 
No studies were located regarding the reproductive effects in
 
humans or animals following oral exposure to chlorobenzene.
 
2.2.2.7 Genotoxic Effects
 
No studies were located regarding genotoxic effects in humans or in
 
vivo studies in animals following oral exposure to chlorobenzene.
 
2.2.2.8 Cancer
 
No studies were located regarding carcinogenic effects in humans
 
following oral exposure to chlorobenzene.
 
In a chronic oral bioassay in rats and mice (NTP 1985), there was
 
no evidence for carcinogenicity in both sexes of mice or female rats
 
administered chlorobenzene in corn oil by gavage at dose levels up to
 
120 mg/kg/day. Increased tumor frequencies were not seen in female rats
 
or in male or female mice. Male rats showed a significant (p < 0.05)
 
increase in the incidence of neoplastic nodules of the liver in the
 
120 mg/kg/day dose group, but no increases were found at lower dose
 
levels. While progression from nodules to carcinomas is a well
 
characterized phenomenon, existing data are inadequate to characterize
 
the carcinogenic potential of chlorobenzene in humans. On the basis of
 
these data, the EPA has classified chlorobenzene as a class D carcinogen
 
(i.e., inadequate evidence of carcinogenicity in humans and animals)
 
(EPA 1987c).
 
2.2.3 Dermal Exposure
 
No studies were located regarding the following effects in humans
 
or animals following dermal exposure to chlorobenzene.
 
2.2.3.1 Death 
2.2.3.2 Systemic Effects 
2.2.3.3 Immunological Effects 
2.2.3.4 Neurological Effects 
2.2.3.5 Developmental Effects 
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2.2.3.6 Reproductive Effects 
2.2.3.7 Genotoxic Effects 
2.2.3.8 Cancer 
2.3 TOXICOKINETICS 
2.3.1 Absorption
 
2.3.1.1 Inhalation Exposure
 
Ogata and Shimada (1983) reported that in two workers exposed to
 
0.84 and 0.5 ppm of chlorobenzene, the amount absorbed was 38% and 45%,
 
respectively of the administered dose. It should be noted that the
 
percent recovery reported in this study did not take into consideration
 
elimination that occurred during the night nor of expired chlorobenzene.
 
Sullivan et al. (1983) reported that rats readily absorbed 14C-labeled
 
chlorobenzene vapor at concentrations up to 700 ppm.
 
2.3.1.2 Oral Exposure
 
Chlorobenzene is absorbed from the gastrointestinal tract. In a
 
study with a single human volunteer, Ogata and Shimada (1983) reported
 
that at least 31% of administered chlorobenzene was absorbed. In the
 
same study, rats administered chlorobenzene absorbed at least 18% of the
 
administered dose. Similar results were reported by Lindsay-Smith
 
et al. (1972), who observed that in rabbits administered 14C-labeled
 
chlorobenzene, at least 22% of the administered chlorobenzene was
 
absorbed.
 
2.3.1.3 Dermal Exposure
 
No studies were located regarding dermal exposure to chlorobenzene
 
in humans or animals.
 
2.3.2 Distribution
 
2.3.2.1 Inhalation Exposure
 
No studies were located regarding distribution after inhalation
 
exposure of chlorobenzene in humans.
 
Sullivan et al. (1983) reported the distribution of 14C-labeled
 
chlorobenzene vapor in rat tissues following single or multiple 8-hour
 
exposures. Some rats were maintained for 48 hours for urine collection.
 
Others were sacrificed immediately or 16 hours after exposure for
 
analysis of tissue radioactivity. The radioactivity in all tissues,
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except for fat, increased in proportion to the increase in exposure
 
concentration. The amount of the radiolabel in adipose tissue increased
 
8 to 10 times when the concentration was increased from 100 to 400 ppm
 
and 3 to 5 times from 400 to 700 ppm. Tissue levels of radioactivity
 
following a single exposure were highest in epididymal and perirenal fat
 
(16.4 and 15.3 micromoles per gram, respectively) after the 700 ppm
 
exposure. These values were not exceeded in animals following multiple
 
exposures. However, multi-exposed rats exhibited higher tissue burdens,
 
48 hours after the last exposure, than rats exposed only once. The
 
preferential distribution of chlorobenzene to the adipose tissue
 
reflects the lipophilic nature (log octanol/water partition coefficient:
 
2.84 (Verschueren 1983)) of this compound. The longevity of
 
radioactivity in fat tissue was not determined.
 
2.3.2.2 Oral Exposure
 
No studies were located regarding the distribution of chlorobenzene
 
after oral exposure in humans or animals.
 
2.3.2.3 Dermal Exposure
 
No studies were located regarding the distribution of chlorobenzene
 
after dermal exposure in humans or animals.
 
2.3.3 Metabolism
 
The proposed metabolic pathway (adapted from Ogata and Shimada
 
1983) of chlorobenzene is shown in Figure 2-3. The main metabolites of
 
chlorobenzene are p-chlorophenylmercapturic acid and 4-chlorocatechol.
 
The in vitro metabolites of chlorobenzene are o-chlorophenol,
 
m-chlorophenol, and p-chlorophenol; the proportions differ according to
 
the source of the mono-oxygenase system and its state of purity
 
(Selander et al. 1975). The o- and p-chlorophenols result from
 
isomerization of the intermediate 3- and 4-chlorobenzene oxides,
 
respectively. The formation of m-chlorophenol appears to occur via a
 
direct oxidative pathway (Oesch et al. 1973). In vitro conjugation of
 
the arene oxide with glutathione or hydration is not a significant
 
pathway (Selander et al. 1975).
 
Ogata and Shimada (1983) examined the urinary metabolites of
 
chlorobenzene in human subjects. An oral dose of 0.3 mmol/kg
 
chlorobenzene was given to a 57-year-old male subject. Metabolites were
 
also assayed in 2 workers exposed via inhalation of either 0.84 or
 
0.5 ppm of chlorobenzene. They reported the occurrence of
 
4-chlorocatechol and p-chlorophenylmercapturic acid in the urine of
 
humans who received chlorobenzene orally or by inhalation.
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Ogata and Shimada (1983) also examined the urinary metabolites of
 
chlorobenzene in rats, mice, and rabbits. Rats were given oral doses of
 
0.3 mmol/kg, while all three species received intraperitoneal injections
 
of 0.5, 1.0, or 2.0 mmol/kg. Urinary p-chlorophenylmercapturic acid,
 
and 4-chlorocatechol, after hydrolysis of its conjugate, were reported.
 
Lindsay-Smith et al. (1972) reported that the major metabolites of
 
chlorobenzene in the rabbit are p-chlorophenylmercapturic acid and
 
conjugates of 4-chlorocatechol. Other urinary metabolites included
 
quinol, 3-chlorocatechol, and o- and m-chlorophenylmercapturic acids.
 
Oesch et al. (1973) studied the metabolism of chlorobenzene in rats
 
administered chlorobenzene by intraperitoneal injection. Thirty-three
 
percent of the administered dose was excreted in the urine, with
 
p-chlorophenol as the major metabolite. Other metabolites included
 
4-chlorocatechol, o-chlorophenol, and m-chlorophenol.
 
2.3.4 Excretion
 
2.3.4.1 Inhalation Exposure
 
Rats were exposed to 14C-chlorobenzene vapor at concentrations of
 
100, 400, and 700 ppm for 8 hours (Sullivan et al. 1983). The plasma
 
concentration-time profile for chlorobenzene on cessation of exposure,
 
as estimated by respiratory elimination of radioactivity, indicated a
 
two compartment elimination. Increase in exposure by a factor of seven
 
(100-700 ppm) increased the total uptake of radioactivity by a factor of
 
about 13. This increase in body burden was associated with a decrease
 
in total body clearance, as indicated by an approximate four fold
 
increase in the half-life of the central compartment. The proportion of
 
the dose excreted via the lungs (which may be presumed to be largely, if
 
not entirely, unchanged chlorobenzene) increased nonlinearly and the
 
proportion eliminated by hepatic metabolism decreased. Increase in the
 
dose of chlorobenzene was associated with a decrease in the proportion
 
cleared as the mercapturic acid derivative. Of interest, the half-life
 
of chlorobenzene was shorter at the 700 ppm exposure level when the
 
animals were subjected to repeated treatment daily for 5 days, as
 
compared with that of the single 700 ppm exposure animals, raising the
 
possibility of induction of metabolic clearance. In agreement with this
 
possibility, the proportion cleared by metabolism in the multi-exposed
 
animals was increased, and the proportion excreted unchanged via the
 
lung was decreased, as compared with the 700 ppm-single exposure
 
animals.
 
Ogata and Shimada (1983) reported that in two workers exposed to
 
0.84 and 0.5 ppm of chlorobenzene, the excretion of
 
p-chlorophenylmercapturic acid was markedly lower than that of
 
4-chlorocatechol. However, the ratio of mercapturic-acid to
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4-chlorocatechol in the urine of human subjects receiving chlorobenzene
 
orally was similar to that of workers inhaling chlorobenzene.
 
2.3.4.2 Oral Exposure
 
Ogata and Shimada (1983) also assayed the urinary metabolites of
 
chlorobenzene of a 57-year-old male volunteer given an oral dose of
 
0.3 mmol/kg of chlorobenzene. Two urinary metabolites,
 
p-chlorophenylmercapturic acid and 4-chlorocatechol, were detected. As
 
in the case of inhalation exposure, the excretion of p-chlorophenylmer­
capturic acid was reported to be markedly lower than that of 4­
chlorocatechol. However, the ratio of mercapturic-acid to 4­
chlorocatechol in the urine of human subjects receiving oral
 
chlorobenzene was similar to that of workers inhaling chlorobenzene.
 
Lindsay-Smith et al. (1972) reported that rabbits administered
 
14C-labeled chlorobenzene excreted 22% of the radiolabel in the urine.
 
The authors concluded that the remaining radiolabel was excreted in the
 
expired air. Ogata and Shimada (1983) reported that in rats the primary
 
urinary metabolite was p-chlorophenylmercapturic acid and that
 
4-chloroatechol was a minor metabolite.
 
2.3.4.3 Dermal Exposure
 
No studies were located concerning excretion of chlorobenzene in
 
animals or man after dermal exposure.
 
2.4 RELEVANCE TO PUBLIC HEALTH
 
Inhalation studies in humans and animals and oral studies in
 
animals demonstrate that chlorobenzene can affect the central nervous
 
system, liver, and kidneys. Chlorobenzene did not affect the developing
 
fetus, was not genotoxic, and did not affect reproduction. Data has not
 
provided clear evidence that chlorobenzene causes cancer in animals.
 
Existing data are considered inadequate to derive human minimal risk
 
levels for acute and chronic exposures.
 
Death. No case studies of human fatalities have been reported
 
following exposure to chlorobenzene by inhalation, ingestion, or dermal
 
contact. Death has been reported in animals at high doses for brief
 
periods of exposure. Rabbits died within 2 weeks after removal from
 
exposure at approximately 537 ppm (Rozenbaum et al. 1947). The cause of
 
death has been attributed to central nervous system depression resulting
 
in respiratory failure. Animal data suggest that lethality may not be a
 
concern for humans unless the exposure level is very high.
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Systemic Effects. No studies were located regarding effects on the
 
respiratory, cardiovascular, gastrointestinal, hematological,
 
musculoskeletal, or dermal/ocular systems in humans or animals by any
 
route of exposure to chlorobenzene.
 
Hepatic Effects. No studies were located demonstrating that
 
chlorobenzene causes hepatic toxicity in humans by any route of
 
exposure. Acute and intermediate exposures in animals demonstrated that
 
chlorobenzene causes changes in liver weights and enzyme levels,
 
degeneration, necrosis, and alterations in microsomal enzymes. These
 
effects were first evident during acute exposure (5 days) at
 
1,140 mg/kg/day by gavage (Rimington and Ziegler 1963) and intermediate
 
exposure (5 days/wk for 24 weeks) at 75 ppm via inhalation (Dilley
 
1977). Similar effects were also observed following ingestion of
 
>250 mg chlorobenzene/kg/day for 91 days. The precise mechanism for
 
liver damage is not known; however, direct binding of chlorobenzene
 
metabolites to cellular protein may be involved (Reid et al. 1973; Reid
 
and Krishna 1973). There were differential sensitivities in animal
 
species tested which may be due to differences in metabolism. Based on
 
animal studies, liver toxicity may be an area of concern in humans.
 
Renal Effects. No studies were located demonstrating that
 
chlorobenzene causes renal effects in humans by any route of exposure.
 
Intermediate studies in animals showed effects on the kidney at doses
 
comparable to those causing liver effects. Typical signs included
 
tubular degeneration and necrosis as well as changes in organ weight.
 
Changes in organ weights with accompanying histopathology occurred at
 
>250 mg/kg/day (90 days) (Kluwe et al. 1985). The precise mechanism of
 
kidney damage is not clear. However, necrosis was associated with
 
covalent binding of substantial amounts of radiolabeled chlorobenzene to
 
kidney protein in intraperitoneal studies (Reid 1973). This study also
 
reported that autoradiograms revealed that most of the covalently bound
 
material was localized within necrotic tubular cells (Reid 1973). Based
 
on animal studies, renal toxicity may be an area of concern in humans.
 
Immunological Effects. Histopathologic evaluations in animals
 
suggest that chlorobenzene may be immunotoxic; however, direct tests of
 
immune function have not been performed. In the absence of functional
 
assessment, the potential for chlorobenzene to affect the immune system
 
in humans can not be determined.
 
Neurological effects. Case reports of humans demonstrated that
 
chlorobenzene caused disturbances of the central nervous system, but
 
there were no reports of changes in the structure of the brain and other
 
parts of the nervous system. Effects were observed in humans who
 
inhaled vapors of chlorobenzene in the workplace for up to 2 years
 
(Rozenbaum et al. 1947). Effects included headaches, dizziness, and
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sleepiness. Unconsciousness, lack of response to skin stimuli, and
 
muscle spasms were noted following accidental ingestion. While there is
 
qualitative evidence for central nervous system effects in humans, a
 
quantitative assessment can not be made since exposure levels were not
 
reported. Because work practices have changed significantly since these
 
studies, it is reasonable to assume that exposure levels in this study
 
were higher than current permissible federal exposure levels. Acute
 
studies in animals confirm that chlorobenzene is potentially neurotoxic.
 
These effects appear to be the result of narcotic effects of
 
chlorobenzene on the central nervous system. Acute inhalation exposure
 
produced narcosis preceded by muscle spasms in rabbits at 1,090 ppm
 
(Rozenbaum et al. 1947).
 
Developmental Effects. No studies were found regarding the
 
developmental toxicity of chlorobenzene in humans. In inhalation and
 
oral exposure studies, the animals did not demonstrate significant
 
developmental toxicity when compared with untreated controls. Negative
 
responses in two animal species suggest that developmental toxicity may
 
not be an area of concern for chlorobenzene.
 
Reproductive Effects. No studies were found regarding the
 
reproductive toxicity of chlorobenzene in humans. In a two-generation
 
inhalation study, chlorobenzene did not adversely affect various
 
reproductive parameters in rats (Nair et al. 1987). While results of
 
this study suggest reproductive toxicity may not be an area of concern
 
to humans, other considerations are warranted before firm conclusions
 
can be made regarding risk to humans. The slight increase in the
 
occurrence of degeneration of the germinal epithelium of the testes
 
provides some evidence for further consideration. Also, the study did
 
not provide histopathological data on other organs related to
 
reproductive functions (i.e., epididymis, vas deferens, accessory sex
 
glands, and pituitary). While the authors reported no treatment-related
 
impairment of fertility, it should be noted that fertility assessments
 
in test animals are limited by their insensitivity as measures of
 
reproductive injury in humans.
 
Genotoxic Effects. No studies were located regarding the genotoxic
 
effects of chlorobenzene in humans. No in vivo animal assays were
 
found, except the micronuclear test in mice which was moderately
 
positive (Mohtashamipur et al. 1987) (Table 2-3). Furthermore, in vitro
 
tests employing bacterial and yeast assay systems with and without
 
metabolic activation were negative (Haworth et al. 1983; NTP 1985;
 
Prasad 1970). Chlorobenzene induced transformation in adult rat liver
 
epithelial cells but was not genotoxic to hepatocytes (Shimada et al.
 
1983). Since transformations may occur through nongenotoxic mechanisms,
 
results do not necessarily indicate that chlorobenzene is potentially
 
genotoxic. Results of in vitro assays for chlorobenzene are presented
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in Table 2-4. Existing data suggest that genotoxicity may not be an
 
area of concern for chlorobenzene exposure in humans.
 
Cancer. No studies were found regarding the carcinogenicity of
 
chlorobenzene in humans. In a chronic bioassay in animals,
 
chlorobenzene (up to 120 mg/kg/day) did not produce increased tumor
 
incidences in mice of both sexes or in female rats (NTP 1985). It was
 
noted, however, that male rats showed a statistically significant
 
increase in neoplastic nodules at the highest dose level tested. While
 
there is strong evidence for neoplastic nodules, existing data are
 
inadequate to characterize the potential for chlorobenzene to cause
 
cancer in humans and animals.
 
BIOMARKERS OF EXPOSURE AND EFFECT
 
Biomarkers are broadly defined as indicators signaling events in
 
biologic systems or samples. They have been classified as markers of
 
exposure, markers of effect, and markers of susceptibility (NAS/NRC
 
1989).
 
A biomarker of exposure is a xenobiotic substance or its
 
metabolite(s) or the product of an interaction between a xenobiotic
 
agent and some target molecule or cell that is measured within a
 
compartment of an organism (NAS/NRC 1989). The preferred biomarkers of
 
exposure are generally the substance itself or substance-specific
 
metabolites in readily obtainable body fluid or excreta. However,
 
several factors can confound the use and interpretation of biomarkers of
 
exposure. The body burden of a substance may be the result of exposures
 
from more than one source. The substance being measured may be a
 
metabolite of another xenobiotic (e.g., high urinary levels of phenol
 
can result from exposure to several different aromatic compounds).
 
Depending on the properties of the substance (e.g., biologic half-life)
 
and environmental conditions (e.g., duration and route of exposure), the
 
substance and all of its metabolites may have left the body by the time
 
biologic samples can be taken. It may be difficult to identify
 
individuals exposed to hazardous substances that are commonly found in
 
body tissues and fluids (e.g., essential mineral nutrients such as
 
copper, zinc, and selenium). Biomarkers of exposure to chlorobenzene
 
are discussed in Section 2.5.1.
 
Biomarkers of effect are defined as any measurable biochemical,
 
physiologic, or other alteration within an organism that, depending on
 
magnitude, can be recognized as an established or potential health
 
impairment or disease (NAS/NRC 1989). This definition encompasses
 
biochemical or cellular signals of tissue dysfunction (e.g., increased
 
liver enzyme activity or pathologic changes in female genital epithelial
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cells), as well as physiologic signs of dysfunction such as increased
 
blood pressure or decreased lung capacity. Note that these markers a
 
often not substance specific. They also may not be directly adverse,
 
but can indicate potential health impairment (e.g., DNA adducts).
 
Biomarkers of effects caused by chlorobenzene are discussed in
 
Section 2.5.2.
 
A biomarker of susceptibility is an indicator of an inherent or
 
acquired limitation of an organism's ability to respond to the challenge
 
of exposure to a specific xenobiotic. It can be an intrinsic genetic or
 
other characteristic or a preexisting disease that results in an
 
increase in absorbed dose, biologically effective dose, or target tissue
 
response. If biomarkers of susceptibility exist, they are discussed in
 
Section 2.7, "POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE."
 
2.5.1 	 Biomarkers Used to Identify and/or Quantify Exposure to
 
Chlorobenzene
 
Levels of chlorobenzene and its metabolites have been measured in 
blood, urine, and exhaled air; however, no studies were located linking 
any level of chlorobenzene in humans with a biological effect. Levels 
ranging from 0.05 to 17 mg/L were detected in the blood and 25 to 
120 µg/L in the urine of residents living near a former toxic chemical 
dump, while trace amounts were found in exhaled air (Barkley et al. 
1980). 
2.5.2 Biomarkers Used to Characterize Effects Caused by Chlorobenzene
 
Neurological damage is a characteristic biomarker of effect in
 
humans exposed to chlorobenzene. Additional information on health
 
effects associated with exposure to chlorobenzene can be found in
 
Section 2.2. Various clinical signs and symptoms of people exposed to
 
chlorobenzene which may be monitored include headaches, dizziness,
 
muscle spasms, and cyanosis (from respiratory depression). No data we
 
found on biochemical changes which may exist.
 
Studies in animals suggest that chlorobenzene may also cause injury
 
to the liver. In rats, alkaline phosphatase, SGOT, and delta-amino
 
levulinic acid levels were increased as were liver protoporphyrin and
 
uroporphyrin. Data suggest that the kidneys may be affected following
 
exposure to chlorobenzene as polyuria was noted in rats at high dose
 
levels. Since other chemicals may produce similar effects, these are
 
not specific indicators of chlorobenzene exposure.
 
2.6  INTERACTIONS WITH OTHER CHEMICALS
 
In an attempt to identify the proposed epoxide intermediate of
 
chlorobenzene, Oesch (1973) co-administered the epoxide hydrase
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inhibitor cyclohexane oxide together with chlorobenzene to rats.
 
Instead of increasing the toxicity of chlorobenzene as expected, through
 
the inhibition of epoxide hydrase, cyclohexane oxide actually decreased
 
the metabolism of chlorobenzene and its necrotic toxicity on the liver,
 
suggesting that the metabolism of chlorobenzene is partially responsible
 
for its liver toxicity.
 
2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
 
No studies were located regarding human populations that are
 
unusually susceptible to chlorobenzene. By analogy to other lipophilic
 
chlorinated benzenes such as hexachlorobenzene, which is found in human
 
milk (Weisenberg et al. 1985), nursing infants may be susceptible to
 
chlorobenzene toxicity.
 
2.8 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of
 
the Public Health Service) to assess whether adequate information on the
 
health effects of chlorobenzene is available. Where adequate
 
information is not available, ATSDR, in conjunction with the National
 
Toxicology Program (NTP), is required to assure the initiation of a
 
program of research designed to determine the health effects (and
 
techniques for developing methods to determine such health effects) of
 
chlorobenzene.
 
The following categories of possible data needs have been
 
identified by a joint team of scientists from ATSDR, NTP, and EPA. They
 
are defined as substance-specific informational needs that, if met would
 
reduce or eliminate the uncertainties of human health assessment. In
 
the future, the identified data needs will be evaluated and prioritized,
 
and a substance-specific research agenda will be proposed.
 
2.8.1 Existing Information on Health Effects of Chlorobenzene
 
The existing data on health effects of inhalation, oral, and dermal
 
exposure of humans and animals to chlorobenzene are summarized in
 
Figure 2-4. The purpose of this figure is to illustrate the existing
 
information concerning the health effects of chlorobenzene. Each dot in
 
the figure indicates that one or more studies provide information
 
associated with that particular effect. The dot does not imply anything
 
about the quality of the study or studies. Gaps in this figure should
 
not be interpreted as "data needs" information.
 
As summarized in Figure 2-4, there is a paucity of data on health
 
effects of chlorobenzene in humans. Existing data relate to inhalation
 
and oral exposures. No data were found on dermal exposures.
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The toxicity of chlorobenzene has been studied in animals by oral
 
and inhalation exposures, but there are no data on dermal exposures.
 
Oral studies have focused on systemic toxicity (liver and kidney) and
 
genotoxic and carcinogenic effects. There are inhalation studies
 
evaluating neurologic, developmental, and reproductive effects.
 
2.8.2 Identification of Data Needs
 
Acute-Duration Exposure. No information is available on the
 
effects of acute-duration exposure of humans to chlorobenzene by any
 
route of exposure. Animal studies indicate that acute inhalation and
 
oral exposures can result in death. No other treatment-related effects
 
were reported. There are no data on effects of chlorobenzene following
 
dermal exposure in animals. Since data on effects in humans are not
 
available and animal data are limited to lethality, data are not
 
sufficient to derive an acute MEL. Further studies would be useful to
 
identify target tissues and threshold levels for effects that may exist.
 
Intermediate-Duration Exposure. No studies are available in humans
 
on the effects of intermediate-duration exposure to chlorobenzene by any
 
route. Inhalation and oral studies in animals indicate that the nervous
 
system, liver, and kidneys are principal target tissues following
 
exposure to chlorobenzene. An intermediate oral MRL was derived based
 
on liver effects in rats. There are no data on effects following dermal
 
exposure in animals. Because there is potential for exposure to
 
chlorobenzene through skin contact, additional studies by dermal
 
exposure would add to the database on chlorobenzene toxicity.
 
Chronic-Duration Exposure and Cancer. Limited studies are
 
available on the effects in humans chronically exposed to chlorobenzene
 
via inhalation and suggest that nervous system is a target tissue.
 
Specific exposure data were not provided. No information is available
 
on effects of chlorobenzene in humans following chronic oral or dermal
 
exposure. Inhalation and oral studies in animals identified the same
 
target tissues as for intermediate-duration exposure. One study in rats
 
demonstrated that the immune system can also be adversely affected via
 
oral exposure. Inhalation studies in humans and inhalation and oral
 
studies in animals are sufficient to identify main target tissues. A
 
chronic MRL was not derived since human exposure data were lacking and
 
the one animal study did not evaluate a sufficient number of end points
 
and test animals. Further studies via the dermal route would provide
 
additional toxicity data for an assessment of potential risk to humans.
 
No studies were found in humans regarding the carcinogenic effect
 
of chlorobenzene via inhalation. Since this is the primary route of
 
environmental exposure, additional studies would be useful to assess
 
potential risk to people who may be exposed to low levels of
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chlorobenzene in air near hazardous waste sites. There was no evidence
 
for carcinogenicity in both sexes of mice or female rats following oral
 
exposure to chlorobenzene. Since the animals were tested at the maximum
 
tolerated dose and a no-effect level for tumors in rats and mice has
 
been determined, additional oral studies are not warranted at this time.
 
Genotoxicity. No studies were found on the genotoxic effects of
 
chlorobenzene in humans by any route of exposure. Results of animal
 
assays were mixed. Chlorobenzene induced statistically significant
 
increases in polychromatic erythrocytes containing micronuclei in mice
 
following intraperitoneal injections. Results of cellular
 
transformation assays of rat liver epithelial cells were positive, but
 
chlorobenzene did not induce unscheduled DNA synthesis in primary rat
 
hepatocytes. Studies evaluating the mutagenic potential of
 
chlorobenzene have been negative. Since existing data do not suggest a
 
significant genotoxic risk associated with exposure to chlorobenzene,
 
additional studies are not warranted at this time.
 
Reproductive Toxicity. No studies were found on the reproductive
 
toxicity of chlorobenzene by any route in humans. Chlorobenzene did not
 
affect various reproductive parameters in a two-generation inhalation
 
study in rats. Additional animal studies employing another species
 
would provide further information for assessing potential effects on the
 
reproductive functions of chlorobenzene. These studies should provide
 
histological evaluations of organs related to reproduction function
 
(i.e., epididymis, vas deferens, accessory sex glands, and pituitary)
 
since these organs have not been evaluated. Slight increases in the
 
incidence of degeneration of testicular epithelium are also noteworthy
 
for further consideration.
 
Developmental Toxicity. No studies have been conducted to evaluate
 
the developmental toxicity of chlorobenzene in humans. Chlorobenzene
 
did not affect the developing fetus following inhalation and oral
 
exposures by rats and rabbits. While there is a potential for exposure
 
via the dermal route, the absence of significant effects by the primary
 
exposure route (inhalation) suggests that additional studies may not be
 
needed at this time.
 
Immunotoxicity. There are no data available on the immunotoxicity
 
of chlorobenzene in humans by any route of exposure. Histological
 
examination of organs and tissues of the immunological system in mice
 
and rats provide some evidence that chlorobenzene is potentially
 
immunotoxic. Immune function tests would provide a better assessment of
 
potential immunotoxic effects in humans.
 
Neurotoxicity. Limited data in humans indicate that exposure to
 
chlorobenzene via inhalation and oral exposures can result in effects on
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the nervous system. Clinical signs and symptoms were observed, but
 
histological lesions were not reported. Results of inhalation studies
 
in animals confirm clinical aberrations, but no data were found in
 
animals following oral exposure. Further studies employing other animal
 
species and various dose levels would be useful to determine if similar
 
effects exist following oral and dermal exposures. Although the
 
inhalation of contaminated air is the most probable route of exposure to
 
chlorobenzene, there is also potential for exposure through skin contact
 
or by consumption of contaminated water. Animal studies in which
 
chlorobenzene is administered orally or dermally would allow
 
determination of neurotoxicity by these routes.
 
Epidemiological and Human Dosimetry Studies. No epidemiological
 
studies have been conducted to evaluate the adverse health effects of
 
chlorobenzene. Existing studies are limited to case reports of
 
occupational exposures and identified the nervous system as a target
 
tissue following chronic inhalation of chlorobenzene. Reliable exposure
 
data were not reported. Additional studies which provide quantitative
 
exposure data would be useful in evaluating potential risk to humans and
 
providing a better understanding of levels which lead to effects that
 
may exist.
 
Biomarkers of Exposure and Effect. Parent chlorobenzene and
 
metabolites can be detected in biological tissues and fluids. However,
 
existing methods may not be useful for evaluating the general population
 
as opposed to industrial situations where preexposure levels are
 
established prior to known chlorobenzene exposure. The overall
 
reliability of these biomarkers are further reduced since data are not
 
available on the half-life of chlorobenzene in various biological media.
 
Central nervous system injury is a common effect associated with
 
exposure to vapors of chlorobenzene in humans. Studies in animals
 
suggest that chlorobenzene can also result in damage to the liver and
 
kidneys. Since similar effects occur with exposure to other chemicals,
 
additional studies are needed to identify more specific biomarkers by
 
which to monitor populations living near hazardous waste sites.
 
Absorption, Distribution, Metabolism, and Excretion. The
 
toxicokinetics of chlorobenzene have not been evaluated to any great
 
extent in humans. Limited studies suggest that chlorobenzene can be
 
absorbed following inhalation and oral exposures, but no data were found
 
on absorption following dermal exposure. Based on absorption
 
characteristics of benzene and the high lipid solubility of
 
chlorobenzene, absorption may be significant depending on conditions.
 
Additional studies are needed to determine absorption rates following
 
exposure by all routes.
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Data are also sparse on the distribution of chlorobenzene. No
 
information is available regarding distribution of chlorobenzene in
 
humans by inhalation, oral, or dermal exposure. There are limited
 
animal data which suggest preferential distribution to adipose tissue in
 
rats via inhalation. The kidneys and liver also showed significant
 
amounts of chlorobenzene and rats that received multiple doses exhibited
 
higher tissue burdens than rats exposed only once.
 
The metabolic transformation of chlorobenzene has been evaluated in
 
humans and animals. Although ultimate products of metabolic oxidation
 
are known, the oxidative pathway and possible intermediates have not
 
been established. Principal metabolites have been determined but
 
quantities and ratios differ among species. Additional studies would be
 
useful to determine if these differences affect the toxicity of
 
chlorobenzene.
 
There are limited data on the excretion of chlorobenzene. In
 
humans exposed via the inhalation and oral routes, chlorobenzene and its
 
metabolites were detected in urine and there were differences in
 
excretion patterns via the two routes. Chlorobenzene and its
 
metabolites were also detected in exhaled air of rats following
 
inhalation and in exhaled air and urine in rabbits after oral exposure.
 
The urinary metabolite profile appeared to be dose dependent and there
 
were changes in excretion patterns due to multiple versus single
 
exposures. No data on excretion following dermal exposure are
 
available. Additional studies would be useful in determining the
 
significance of these differences with regard to risk associated with
 
different routes of exposure.
 
Comparative Toxicokinetics. Existing studies regarding
 
toxicokinetics of chlorobenzene in humans are limited, but data do
 
provide some understanding of the absorption, metabolism, and excretion
 
following inhalation and oral exposures. Since studies on distribution
 
of chlorobenzene are lacking, quantitative data correlating human
 
exposure and tissue accumulation would be useful. In animals,
 
quantitative data on absorption, distribution, metabolism, and excretion
 
are very limited in extent and quality. Additional studies using a
 
variety of species and including physiological based pharmacokinetic
 
modeling would be useful in determining the most suitable animal model
 
for assessing human risk.
 
2.8.3 On-going Studies
 
Chlorobenzene is one of 47 chemicals to be tested by NTP for
 
heritable genetic effects in Drosophila and for mutagenesis in the mouse
 
lymphoma cell mutagenesis assay.
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3. CHEMICAL AND PHYSICAL INFORMATION
 
3.1 CHEMICAL IDENTITY
 
Table 3-1 lists common synonyms, trade names and other pertinent
 
identification information for chlorobenzene.
 
3.2 PHYSICAL AND CHEMICAL PROPERTIES
 
Table 3-2 lists important physical and chemical properties of
 
chlorobenzene.
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4. PRODUCTION, IMPORT, USE, AND DISPOSAL
 
4.1 PRODUCTION
 
Production of chlorobenzene in the United States has declined by
 
nearly 60%, from the peak production volume of 274,000 kkg in 1960 to
 
112,000 kkg in 1987. This decline is attributed primarily to the
 
replacement of chlorobenzene by cumene in phenol production and the
 
cessation of DDT production in the United States. In addition,
 
pesticide production using chlorobenzene as an intermediate has declined
 
and no major new uses have been found for chlorobenzene in recent years.
 
Therefore, the decline in chlorobenzene production is expected to
 
continue (EPA 1980c, 1985; Hughes et al. 1983; USITC 1988).
 
Chlorobenzene is produced by three United States chemical
 
companies: Monsanto Chemical Company, Sauget, Illinois; PPG Industries,
 
Inc., Natrium, West Virginia; and Standard Chlorine Chemical Co., Inc.,
 
Delaware City, Delaware. Production capacity for chlorobenzene at these
 
plants has remained constant since 1985 although it appears that actual
 
production has declined slightly during that period (Hughes et al. 1983;
 
SRI 1985, 1986, 1987, 1988; USITC 1988).
 
Chlorobenzene is produced commercially by the chlorination of
 
benzene in the presence of a catalyst (e.g., ferric chloride, aluminum
 
chloride, or stannic chloride). This process yields a mixture of
 
chlorobenzene, dichlorobenzenes, and higher analogs which are distiller
 
and crystallized to obtain pure products (EPA 1985a; Hughes et al.
 
1983).
 
4.2 IMPORT
 
Import and export data for chlorobenzene are not readily available.
 
Estimates indicate that for the last ten years, both imports and exports
 
have been negligible (Hughes et al. 1983).
 
4.3 USE
 
The current primary uses of chlorobenzene are as a solvent for
 
pesticide formulations, diisocyanate manufacture, degreasing automobile
 
parts, and for the production of nitrochlorobenzene. Solvent uses
 
accounted for about 37% of chlorobenzene consumption in the United
 
States in 1981, nitrochlorobenzene production for 33%, and diphenyl
 
oxide and phenylphenol production for 16% of consumption. Chlorobenzene
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is also used in silicone resin production and as an intermediate in the
 
synthesis of other halogenated organics. The past major use of
 
chlorobenzene was as an intermediate in phenol and DDT production
 
(Hughes et al. 1983).
 
4.4 DISPOSAL
 
Because chlorobenzene is listed as a hazardous substance, disposal
 
of waste chlorobenzene is controlled by a number of federal regulations
 
(see Chapter 7). Spent solvent wastes, which may include chlorobenzene,
 
are prohibited from land disposal, except under specific conditions.
 
Land disposal restrictions (treatment standards) are proposed for other
 
wastes containing chlorobenzene. Wastes containing chlorobenzene may be
 
disposed of by liquid injection, rotary kiln, or fluidized bed
 
incineration (EPA 1988a, 1989b; HSDB 1988). Since chlorobenzene is a
 
volatile compound and is used extensively as a solvent, large quantities
 
are released to the air. Some estimates indicate that 30 to 50% of the
 
annual production of chlorobenzene is released to the atmosphere, while
 
less than 0.1% is found in wastewater and less than 1% is disposed of on
 
land (EPA 1985a).
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5. POTENTIAL FOR HUMAN EXPOSURE
 
5.1 OVERVIEW
 
Chlorobenzene is used as a solvent and as an intermediate in
 
industry. A portion of that is lost to the environment in water and air
 
discharges. Chlorobenzene adsorbs moderately to soil and is biodegraded
 
comparatively rapidly. With a moderate index of bioaccumulation,
 
chlorobenzene was found in almost every individual tested for it in the
 
United States. The EPA has identified 1,177 NPL sites. Chlorobenzene
 
has been found at 97 of the sites evaluated for the presence of this
 
chemical. As more sites are evaluated by the EPA, the number may
 
change. The frequency of these sites within the United States can be
 
seen in Figure 5-l.
 
5.2 RELEASES TO THE ENVIRONMENT
 
5.2.1 Air
 
The production of chlorobenzene by seven major producers was
 
reported to be 112,000 kkg in 1987. Estimates of environmental releases
 
vary widely. The EPA (1982d) estimated the release of chlorobenzene to
 
be about 200 tons, or 0.2% of production, while Dow Chemical Company
 
estimated that about 50,000 tons, or 30% to 50% of their annual
 
production was released to the air (EPA 1980a).
 
5.2.2 Water
 
The principal source of chlorobenzene in water is release from 
chemical manufacturing facilities. Dow Chemical Company estimated that 
0.1% of its annual production enters waters (EPA 1980a). Perry et al. 
(1979) found chlorobenzene in 6/63 industrial effluent in concentrations 
up to 100 µg/L. Based on 1,338 samples collected from about 1980 to 
1983, the medium concentration of chlorobenzene in waste effluent was 
< 3 ppb and was detected in 54 samples. The total amount released to 
the environment was not reported (Staples et al. 1985). Chlorobenzene 
has been detected in both surface and groundwater samples at hazardous 
waste sites. Data from the Contract Laboratory Program (CLP) 
Statistical Database indicate that chlorobenzene occurred in surface 
water at 13 sites at a geometric mean concentration of 17 ppb in 
positive samples and in groundwater at 28 sites at a geometric mean 
concentration of 62 ppb in positive samples (CLPSD 1988). It should be 
noted that the CLP Statistical Database includes data from both NPL and 
non-NPL sites. 

49
 
5. POTENTIAL FOR HUMAN EXPOSURE
 
5.2.3 Soil
 
Chlorobenzene was detected at 34 sites at a geometric mean
 
concentration of 37 ppm in positive soil samples (CLPSD 1988). It
 
should be noted that the CLP Statistical Database includes data from
 
both NPL and non-NPL sites.
 
5.3 ENVIRONMENTAL FATE
 
5.3.1 Transport and Partitioning
 
Chlorobenzene is volatile and has only moderate solubility in water
 
(500 mg/L). Chlorobenzene was observed to evaporate (> 99%) from an
 
unaerated aqueous solution in 72 hrs (Garrison and Hill 1972). The air,
 
undoubtedly, plays a large role in the environmental transport and
 
degradation of chlorobenzene, although studies addressing this aspect
 
were not found.
 
5.3.2 Transformation and Degradation
 
5.3.2.1 Air
 
Physical constants for chlorobenzene, especially its vapor pressure
 
and water solubility, indicate that the air is an important and perhaps
 
the dominant medium for the transport and transformation of
 
chlorobenzene. As an aromatic molecule with strong UV-absorption,
 
chlorobenzene has a half-life of 20 to 40 hrs under simulated
 
atmospheric conditions (Dilling et al. 1976). This appears to be
 
confirmed by the large difference between chlorobenzene measurements in
 
urban air (3,000 ng/m3) and in rural air (not detected) in 1982
 
(Brodzinsky and Singh 1983).
 
5.3.2.2 Water
 
Biodegradation in a waste water inoculum was studied by Tabak
 
et al. (1981). Among 57 environmental pollutants tested, chlorobenzene
 
at 5 mg/L was among the more rapidly biodegraded substances with 89%
 
degradation in a week and 100% after adaptation. Biodegradation is
 
therefore a major degradation process in oxygenated waters while
 
evaporation will play an additional role in surface waters.
 
5.3.2.3 Soil
 
Biodegradation of chlorobenzene is rapid, leaving no detectable
 
residues after 1 or 2 weeks. Adaptation is also rapid (Tabak et al.
 
1981).
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5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
 
5.4.1 Air
 
Air samples at 56 localities in the United States in 1982 had mean
 
chlorobenzene concentrations of about 3,000 ng/m3; the highest
 
concentrations in urban and suburban areas, at much lower levels at the
 
sites of production, but was not detectable in rural and remote areas
 
(Brodzinsky and Singh 1983). This suggests a substantial contribution
 
to urban air levels by small industry and consumer products but also a
 
short residence time in the air. A study of New Jersey waste sites
 
found similar air levels of chlorobenzene (2,500 ng/m3) (Harkov et al.
 
1985). However, air levels found by another study done for the United
 
States EPA (Pellizzari 1978a) were an order of magnitude lower, with
 
only the air over a waste site approaching the mean urban concentrations
 
reported above. Ambient air outside homes of "Old Love Canal" (Niagara
 
Falls, New York) contained chlorobenzene ranging from not detectable (4
 
sites) to traces (4 sites) and 120 ng/m3 (1 site) (Barkley et al. 1980).
 
5.4.2 Water
 
Chlorobenzene, along with other chlorinated chemicals, was found in 
United States' rivers at levels up to and exceeding 10,000 ng/L 
(Shackelford and Keith 1976; Sheldon and Hites 1978). Private wells 
near a hazardous waste site contained as much as 41 µg/L (Clark 1982) 
and tap water at Love Canal contained 10 to 60 ng/L of chlorobenzene 
(Barkley et al. 1980). 
Chlorobenzene contamination of industrial waste waters up to and 
exceeding 100 µg/L was found in 6/63 samples (Perry et al. 1979) and in 
147/31,194 samples with a mean concentration of 667 µg/L (EPA 1985a). 
5.4.3 Soil
 
Staples et al. (1985) reported that the median concentration of
 
chlorobenzene in the United States was estimated to be less than 5 ppb
 
dry sediments. In 347 measurements recorded in the STORET data base, 2%
 
of the samples contained detectable concentrations of chlorobenzene.
 
5.4.4 Other Media
 
No studies of chlorobenzene in food or other media are available.
 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
 
Chlorobenzene was found in 98/100 human adipose tissue samples from
 
all regions of the United States at levels ranging from 1 to 9 ng/g
 
(Stanley 1986). At Love Canal, Niagara Falls, chlorobenzene could be
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detected in the breath of one of nine people evaluated for exposure and
 
in the urine of six of nine persons at 20 to 120 ng/L (Barkley et al.
 
1980).
 
Personal sampling at chemical companies (Cohen et al. 1981)
 
indicated that chlorobenzene levels (up to 18 mg/m3) in work place air
 
did not exceed the current federal level (350 mg/m3).
 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
 
Occupational settings provide the greatest potential for high
 
exposures to chlorobenzene. Since chlorobenzene is a volatile compound
 
and is used extensively as a solvent, large quantities may be released
 
to the workplace air. Other populations who might be exposed include
 
persons living near industrial facilities where chlorobenzene emissions
 
are not properly controlled.
 
5.7 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of
 
the Public Health Service) to assess whether adequate information on the
 
health effects of chlorobenzene is available. Where adequate
 
information is not available, ATSDR, in conjunction with the NTP, is
 
required to assure the initiation of a program of research designed to
 
determine the health effects (and techniques for developing methods to
 
determine such health effects) of chlorobenzene.
 
The following categories of possible data needs have been
 
identified by a joint team of scientists from ATSDR, NTP, and EPA. They
 
are defined as substance-specific informational needs that, if met would
 
reduce or eliminate the uncertainties of human health assessment. In
 
the future, the identified data needs will be evaluated and prioritized,
 
and a substance-specific research agenda will be proposed.
 
5.7.1 Identification of Data Needs
 
Physical and Chemical Properties. Physical and chemical properties
 
of chlorobenzene have been thoroughly measured.
 
Production, Use, Release, and Disposal. Data indicate that
 
chlorobenzene production has declined dramatically over the past two
 
decades, but current quantitative data on use (especially solvent uses)
 
and disposal practices would be helpful in evaluating the effect of
 
current industrial practices on environmental levels of chlorobenzene.
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According to the Emergency Planning and Community Right to Know Act
 
of 1986 (EPCRTKA), (§313), (Pub. L. 99-499, Title III, §313), industries
 
are required to submit release information to the EPA. The Toxic
 
Release Inventory (TRI), which contains release information for 1987,
 
became available in May of 1989. This database will be updated yearly
 
and should provide a more reliable estimate of industrial production and
 
emission.
 
Environmental Fate. Information on biodegradation in soil under
 
aerobic conditions exists, but degradation products were not identified.
 
Anaerobic biodegradation, as might occur in river bottoms and in
 
Superfund sites, has not been studied and would be valuable. Emissions
 
from waste lagoons have been modelled and measured in bench-top
 
experiments and are measured as part of many Superfund Remedial
 
Investigation/Feasibility studies, but those were not located.
 
Bioavailability from Environmental Media. Chlorobenzene is
 
absorbed primarily following inhalation of contaminated air. There is
 
also some potential for exposure from water and soil. Chlorobenzene has
 
been detected at low levels in surface, ground, and drinking water, but
 
no information was found on levels in food. Since chlorobenzene binds
 
tightly to soil particles, skin contact with or ingestion of
 
contaminated soil may be an important source of exposure, particularly
 
in children living near hazardous waste sites. Additional studies would
 
be useful to determine if soil-bound chlorobenzene is bioavailable.
 
Food Chain Bioaccumulation. No information is available regarding
 
biomagnification within aquatic or terrestrial food chains. Additional
 
studies would be useful in assessing potential for human exposure to
 
chlorobenzene.
 
Exposure Levels in Environmental Media. There are studies on
 
concentrations of chlorobenzene in air and water, but many of the
 
samples measured had low levels or did not have detectable levels.
 
Additional studies using more sensitive analytical methods would be
 
useful.
 
Exposure Levels in Humans. Studies have been conducted measuring
 
chlorobenzene levels in drinking water and air (including indoor air).
 
Conflicting data on chlorobenzene air levels point to a need for
 
confirmation and, possibly, validation of analytical methods. Less
 
conflicting estimates of environmental emissions are the prerequisite
 
for any attempt to prioritize control measures.
 
Exposure Registries. No exposure registries for chlorobenzene were
 
located. This compound is not currently one of the compounds for which
 
a subregistry has been established in the National Exposure Registry.
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The compound will be considered in the future when chemical selection is
 
made for subregistries to be established. The information that is
 
amassed in the National Exposure Registry facilitates the
 
epidemiological research needed to assess adverse health outcomes that
 
may be related to the exposure to this compound.
 
5.7.2 On-going studies
 
Studies on the migration and in situ biodegradation of
 
chlorobenzene in hazardous waste sites are being conducted in the
 
laboratory of Perry McCarty and others.
 
As part of the Third National Health and Nutrition Evaluation
 
Survey (NHANES III), the Environmental Health Laboratory Sciences
 
Division of the Center for Environmental Health and Injury Control,
 
Centers for Disease Control, will be analyzing human blood samples for
 
chlorobenzene and other volatile organic compounds. These data will
 
give an indication of the frequency of occurrence and background levels
 
of these compounds in the general population.
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The purpose of this chapter is to describe the analytical methods
 
that are available for detecting and/or measuring and monitoring
 
chlorobenzene in environmental media and in biological samples. The
 
intent is not to provide an exhaustive list of analytical methods that
 
could be used to detect and quantify chlorobenzene. Rather, the
 
intention is to identify well-established methods that are used as the
 
standard methods of analysis. Many of the analytical methods used to
 
detect chlorobenzene in environmental samples are methods approved by
 
federal agencies such as EPA and the National Institute for Occupational
 
Safety and Health (NIOSH). Other methods presented in this chapter are
 
those that are approved by a trade association such as the Association
 
of Official Analytical Chemists (AOAC) and the American Public Health
 
Association (APHA). Additionally, analytical methods are included that
 
refine previously used methods to obtain lower detection limits, and/or
 
to improve accuracy and precision.
 
BIOLOGICAL MATERIALS
 
Many of the considerations regarding the analysis of halogenated 
alkanes and alkenes in biological samples (Fishbein 1985) similarly 
apply to the determination of chlorobenzene in these samples. Although 
most environmentally significant halogenated alkanes and alkenes have 
boiling points below 100°C, chlorobenzene is relatively less volatile 
with a boiling point of 132°C. The water solubility (25°C) of 
chlorobenzene is 472 mg/L, which is lower than the water solubilities of 
most environmentally and toxicologically significant halogenated alkanes 
and alkenes. Along with many halogenated alkanes and alkenes, 
chlorobenzene is classified as a purgeable species for purge-and-trap 
analysis (EPA 1982a, 1982b). Therefore, many of the approaches and 
methods used for the determination of halogenated alkanes and alkenes in 
biological samples are applicable to chlorobenzene, although they have 
not been validated as a sampling method. 
Because chlorobenzene is volatile, has limited water solubility,
 
and has a moderate affinity for lipid tissue, chlorobenzene is easily
 
lost from biological samples. Appropriate care must be exercised in
 
handling and storing such samples for analysis of chlorobenzene.
 
The methods that generally are used to remove volatile organic
 
chemicals (VOCs) from biological samples for analysis are applicable to
 
chlorobenzene. These include headspace analysis, purge-and-trap (gas
 
stripping) collection from aqueous solutions or slurry samples, solvent
 
extraction, and direct collection on resins. Headspace analysis offers
 
speed, simplicity, and good reproducibility for a particular type of
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sample. However, partitioning of the analyte between the headspace and
 
the sample matrix is dependent upon the nature of the matrix and must be
 
determined separately for different kinds of matrices (Walters 1986).
 
Purge-and-trap collection is well suited to biological samples that
 
are soluble in water and is readily adapted to biological samples from
 
techniques that have been developed for the analysis of halocarbons such
 
as chlorobenzene in water and wastewater. For water-insoluble
 
materials, the purge-and-trap approach is complicated by the uncertainty
 
of partitioning the analyte between sample slurry particles and water.
 
Homogenization of tissue with the extractant and lysing of cells
 
improves extraction efficiency. When multiple analytes are determined
 
using solvent extraction, selective extraction and loss of low-boiling
 
compounds can cause errors. The commercial availability of highly
 
purified solvents has largely eliminated problems with solvent
 
impurities, although high costs, solvent toxicities, and restrictions on
 
spent solvent disposal must be considered. Directly coupled
 
supercritical fluid extraction-gas chromatography has been used for the
 
determination of polychlorinated biphenyls (Hawthorne 1988) and should
 
work well for the determination of chlorobenzene in biological samples.
 
Analytical methods for the determination of chlorobenzene in
 
biological samples are given in Table 6-1.
 
ENVIRONMENTAL SAMPLES
 
Purgeable organic compounds such as chlorobenzene can be determined 
in water by the purge-and-trap technique. This method consists of 
bubbling inert gas through a small volume of the sample and collecting 
the vapor in a trap packed with sorbent. The analytes are then removed 
from the trap by heating it and backflushing the analytes onto a gas 
chromatographic column. The two materials most widely used for 
adsorption and thermal desorption of volatile organic compounds 
collected by the purge-and-trap technique are Carbotrap consisting of 
graphitized carbon black, and Tenax a porous polymer of 2,6-diphenyl­
pphenylene oxide (Fabbri et al. 1987). 
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The introduction of capillary column chromatography has markedly 
improved both the sensitivity and resolution of gas chromatographic 
analysis of environmental samples such as chlorobenzene. Because of the 
very small quantities of sample required, capillary column chromatography 
has made sample delivery more difficult. One of the more 
promising approaches to sample introduction using capillary columns with 
purge-and-trap collection is the use of cryofocussing. Basically, this 
procedure consists of collecting purged analyte on a short section of 
the capillary column cooled to a low temperature (e.g., -100°C) 
temperature, followed by heating and backflushing of the sample onto the 
analytical column. Chlorobenzene has been determined in water by this 
method (Washall and Wampler 1988). 
Chlorobenzene can be removed from water by adsorption on synthetic 
polymers contained in cartridges, followed by thermal desorption of 
analyte (Pankow et al. 1988). Among the products used for this purpose 
are Tenax-GC and Tenax-TA . 
Analytical methods for the determination of chlorobenzene in
 
environmental samples are given in Table 6-2.
 
ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of
 
the Public Health Service) to assess whether adequate information on the
 
health effects of chlorobenzene is available. Where adequate
 
information is not available, ATSDR, in conjunction with the NTP, is
 
required to assure the initiation of a program of research designed to
 
determine the health effects (and techniques for developing methods to
 
determine such health effects) of chlorobenzene.
 
The following categories of possible data needs have been
 
identified by a joint team of scientists from ATSDR, NTP, and EPA. They
 
are defined as substance-specific informational needs that, if met would
 
reduce or eliminate the uncertainties of human health assessment. In
 
the future, the identified data needs will be evaluated and prioritized,
 
and a substance-specific research agenda will be proposed.
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6.3.1 Identification of Data Needs
 
Methods for Determining Biomarkers of Exposure and Effect.
 
Excellent sensitive and selective methods are available for the
 
qualitative and quantitative measurement of the parent compound,
 
chlorobenzene after it is separated from its sample matrix. Methods
 
need to be validated for chlorobenzene.
 
Further studies on the transfer analytes that have been purged or
 
extracted from a biological or environmental sample quantitatively and
 
in a narrow band to the capillary GC would better characterize exposure.
 
Improvements in cryofocussing of VOC analytes for capillary GC
 
determination of VOCs (Washall and Wampler 1988) should improve
 
sensitivity for the determination of chlorobenzene.
 
Metabolites of chlorobenzene in biological materials cannot be
 
determined in routine practice because of the lack of standard methods
 
for measuring these metabolites. Further research on supercritical
 
fluid (SCF) extraction holds great promise for meeting the goals of
 
quantitative, rapid, easily performed, low cost, and safe procedures for
 
the determination of nonpolar organic analytes such as chlorobenzene in
 
biological samples.
 
Central nervous system, liver, and kidney injuries are characteristic
 
biomarkers for effects of chlorobenzene intoxication. Since the effects
 
are indicative of exposure to many other toxicants, methods are needed
 
for more specific biomarkers.
 
Methods for Determining Parent Compounds and Degradation Products in
 
Environmental Media. Methods for determining the parent compound,
 
chlorobenzene, in water, air, and waste samples with excellent
 
selectivity and sensitivity are highly developed, thus the database in
 
this area is good and undergoing constant improvement.
 
Means to measure organohalides such as chlorobenzene in situ in
 
water and other environmental media could contribute to environmental
 
studies of this compound.
 
Degradation products of chlorobenzene in environmental media are
 
difficult to determine. This difficulty is not so much an analytical
 
problem as it is a problem of knowing the fundamental environmental
 
chemistry of these compounds in water, soil, air, and biological
 
systems.
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6.3.2 On-going Studies
 
Research is ongoing to develop a "Master Analytical Scheme" for 
organic compounds in water (Michael et al. 1988), which includes 
chlorobenzene as an analyte. The overall goal is to detect and 
quantitatively measure organic compounds at 0.1 µg/L in drinking water, 
1 µg/L in surface waters, and 10 µg/L in effluent waters. Analytes are 
to include numerous semivolatile compounds and some compounds that are 
only "semi-soluble" in water, as well as volatile compounds 
(bp < 150°C). 
The Environmental Health Laboratory Sciences Division of the Center
 
for Environmental Health and Injury Control, Centers for Disease
 
Control, is developing methods for the analysis of chlorobenzene and
 
other volatile organic compounds in blood. These methods use purge and
 
trap and magnetic mass sector spectrometry which gives detection limits
 
in the low parts per trillion range.
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Because of its potential to cause adverse health effects in exposed
 
people, a number of regulations and advisories have been established for
 
chlorobenzene by various national and state agencies. These values are
 
summarized in Table 7-1.
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9. GLOSSARY
 
Acute Exposure -- Exposure to a chemical for a duration of 14 days or
 
less, as specified in the Toxicological Profiles.
 
Adsorption Coefficient (K
oc
) -- The ratio of the amount of a chemical
 
adsorbed per unit weight of organic carbon in the soil or sediment to
 
the concentration of the chemical in solution at equilibrium.
 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment
 
or soil (i.e., the solid phase) divided by the amount of chemical in the
 
solution phase, which is in equilibrium with the solid phase, at a fixed
 
solid/solution ratio. It is generally expressed in micrograms of
 
chemical sorbed per gram of soil or sediment.
 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a
 
chemical in aquatic organisms at a specific time or during a discrete
 
time period of exposure divided by the concentration in the surrounding
 
water at the same time or during the same time period.
 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study or
 
group of studies which produces significant increases in incidence of
 
cancer (or tumors) between the exposed population and its appropriate
 
control.
 
Carcinogen -- A chemical capable of inducing cancer.
 
Ceiling value (CL) -- A concentration of a substance that should not be
 
exceeded, even instantaneously.
 
Chronic Exposure -- Exposure to a chemical for 365 days or more, as
 
specified in the Toxicological Profiles.
 
Developmental Toxicity -- The occurrence of adverse effects on the
 
developing organism that may result from exposure to a chemical prior to
 
conception (either parent), during prenatal development, or postnatally
 
to the time of sexual maturation. Adverse developmental effects may be
 
detected at any point in the life span of the organism.
 
Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as
 
a result of prenatal exposure to a chemical; the distinguishing feature
 
between the two terms is the stage of development during which the
 
insult occurred. The terms, as used here, include malformations and
 
variations, altered growth, and in utero death.
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EPA Health Advisory -- An estimate of acceptable drinking water levels
 
for a chemical substance based on health effects information. A health
 
advisory is not a legally enforceable federal standard, but serves as
 
technical guidance to assist federal, state, and local officials.
 
Immediately Dangerous to Life or Health (IDLH) -- The maximum
 
environmental concentration of a contaminant from which one could escape
 
within 30 min without any escape-impairing symptoms or irreversible
 
health effects,
 
Intermediate Exposure -- Exposure to a chemical for a duration of 15-364
 
days, as specified in the Toxicological Profiles.
 
Immunologic Toxicity -- The occurrence of adverse effects on the immune
 
system that may result from exposure to environmental agents such as
 
chemicals.
 
In Vitro -- Isolated from the living organism and artificially
 
maintained, as in a test tube.
 
In Vivo -- Occurring within the living organism.
 
Lethal Concentration(LO) (LCLO) -- The lowest concentration of a chemical
 
in air which has been reported to have caused death in humans or
 
animals.
 
Lethal Concentration(50) (LC50) -- A calculated concentration of a
 
chemical in air to which exposure for a specific length of time is
 
expected to cause death in 50% of a defined experimental animal
 
population.
 
Lethal Dose(LO) (LDLO) -- The lowest dose of a chemical introduced by a
 
route other than inhalation that is expected to have caused death in
 
humans or animals.
 
Lethal Dose(50) (LD50) -- The dose of a chemical which has been
 
calculated to cause death in 50% of a defined experimental animal
 
population.
 
Lethal Time(50)(LT50) -- A calculated period of time within which a
 
specific concentration of a chemical is expected to cause death in 50%
 
of a defined experimental animal population.
 
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of
 
chemical in a study or group of studies which produces statistically or
 
biologically significant increases in frequency or severity of adverse
 
effects between the exposed population and its appropriate control.
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Malformations -- Permanent structural changes that may adversely affect
 
survival, development, or function.
 
Minimal Risk Level (MRL) -- An estimate of daily human exposure to a
 
chemical that is likely to be without an appreciable risk of deleterious
 
effects (noncancerous) over a specified duration of exposure.
 
Mutagen -- A substance that causes mutations. A mutation is a change in
 
the genetic material in a body cell. Mutations can lead to birth
 
defects, miscarriages, or cancer.
 
Neurotoxicity -- The occurrence of adverse effects on the nervous system
 
following exposure to a chemical.
 
No-Observed-Adverse-Effect Level (NOAEL) -- That dose of chemical at
 
which there are no statistically or biologically significant increases
 
in frequency or severity of adverse effects seen between the exposed
 
population and its appropriate control. Effects may be produced at this
 
dose, but they are not considered to be adverse.
 
Octanol-Water Partition Coefficient (K
ow
) -- The equilibrium ratio of
 
the concentrations of a chemical in n-octanol and water, in dilute
 
solution.
 
Permissible Exposure Limit (PEL) -- An allowable exposure level in
 
workplace air averaged over an 8-hour shift.
 
q1* -- The upper-bound estimate of the low-dose slope of the doseresponse 
curve as determined by the multistage procedure. The q1* can 
be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for 
water, mg/kg/day for food, and µg/m3 for air). 
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps
 
an order of magnitude) of the daily exposure of the human population to
 
a potential hazard that is likely to be without risk of deleterious
 
effects during a lifetime. The RfD is operationally derived from the
 
NOAEL (from animal and human studies) by a consistent application of
 
uncertainty factors that reflect various types of data used to estimate
 
RfDs and an additional modifying factor, which is based on a
 
professional judgment of the entire database on the chemical. The RfDs
 
are not applicable to nonthreshold effects such as cancer.
 
Reportable Quantity (RQ) -- The quantity of a hazardous substance that
 
is considered reportable under CERCLA. Reportable quantities are: (1) 1
 
lb or greater or (2) for selected substances, an amount established by
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regulation either under CERCLA or under Sect. 311 of the Clean Water
 
Act. Quantities are measured over a 24-hour period.
 
Reproductive Toxicity -- The occurrence of adverse effects on the
 
reproductive system that may result from exposure to a chemical. The
 
toxicity may be directed to the reproductive organs and/or the related
 
endocrine system. The manifestation of such toxicity may be noted as
 
alterations in sexual behavior, fertility, pregnancy outcomes, or
 
modifications in other functions that are dependent on the integrity of
 
this system.
 
Short-Term Exposure Limit (STEL) -- The maximum concentration to which
 
workers can be exposed for up to 15 min continually. No more than four
 
excursions are allowed per day, and there must be at least 60 min
 
between exposure periods. The daily TLV-TWA may not be exceeded.
 
Target Organ Toxicity -- This term covers a broad range of adverse
 
effects on target organs or physiological systems (e.g., renal,
 
cardiovascular) extending from those arising through a single limited
 
exposure to those assumed over a lifetime of exposure to a chemical.
 
Teratogen -- A chemical that causes structural defects that affect the
 
development of an organism.
 
Threshold Limit Value (TLV) -- A concentration of a substance to which
 
most workers can be exposed without adverse effect. The TLV may be
 
expressed as a TWA, as a STEL, or as a CL.
 
Time-weighted Average (TWA) -- An allowable exposure concentration
 
averaged over a normal 8-hour workday or 40-hour workweek.
 
Toxic Dose (TD50) -- A calculated dose of a chemical, introduced by a
 
route other than inhalation, which is expected to cause a specific toxic
 
effect in 50% of a defined experimental animal population.
 
Uncertainty Factor (UF) -- A factor used in operationally deriving the
 
RfD from experimental data. UFs are intended to account for (1) the
 
variation in sensitivity among the members of the human population, (2)
 
the uncertainty in extrapolating animal data to the case of humans, (3)
 
the uncertainty in extrapolating from data obtained in a study that is
 
of less than lifetime exposure, and (4) the uncertainty in using LOAEL
 
data rather than NOAEL data. Usually each of these factors is set equal
 
to 10.
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PEER REVIEW
 
A peer review panel was assembled for chlorobenzene. The panel
 
consisted of the following members: Dr. David Jollow, Professor in the
 
Department of Pharmacology, Medical University of South Carolina,
 
Charleston, South Carolina; Dr. Henry Peters, Professor in the
 
Department of Neurology, University of Wisconsin Clinical Science
 
Center, Madison, Wisconsin; Dr. Jay B. Silkworth, Research Scientist,
 
Wadsworth Center Labs, New York Department of Health, Albany, New York;
 
Dr. Frank Lu, Private Toxicology Consultant, Miami, Florida; Dr. James
 
Pollard, Private Consultant, Las Vegas, Nevada. These experts
 
collectively have knowledge of chlorobenzene's physical and chemical
 
properties, toxicokinetics, key health end points, mechanisms of action,
 
human and animal exposure, and quantification of risk to humans. All
 
reviewers were selected in conformity with the conditions for peer
 
review specified in Section 104(i)(13) of the Comprehensive
 
Environmental Response, Compensation, and Liability Act, as amended.
 
A joint panel of scientists from ATSDR and EPA has reviewed the
 
peer reviewers' comments and determined which comments will be included
 
in the profile. A listing of the peer reviewers' comments not
 
incorporated in the profile, with a brief explanation of the rationale
 
for their exclusion, exists as part of the administrative record for
 
this compound. A list of databases reviewed and a list of unpublished
 
documents cited are also included in the administrative record.
 
The citation of the peer review panel should not be understood to
 
imply their approval of the profile's final content. The responsibility
 
for the content of this profile lies with the Agency for Toxic
 
Substances and Disease Registry.
 

